EDX Medical Group PLC Annual General Meeting Results
September 30 2024 - 9:40AM
RNS Regulatory News
RNS Number : 3032G
EDX Medical Group PLC
30 September 2024
EDX Medical
Group Plc · EDX
AQSE:
EDX
("EDX
Medical" or the "Company")
30
September 2024
Annual General Meeting
Result of Annual General
Meeting
The Annual General Meeting of EDX Medical Group
plc was held at Mezzanine Room, 1 Wimpole Street, Westminster,
London, W1G 0AE on 30 September 2024 at 2:00 p.m.
All 11 resolutions put to members were passed
on a poll. Resolutions 1 to 9 were passed as ordinary resolutions
and resolutions 10 and 11 were passed as special
resolutions.
The number of votes cast for and against each
of the resolutions proposed, and the number of votes withheld were
as follows:
|
Resolution
|
Votes for
|
%
|
Votes against
|
%
|
Votes withheld
|
|
Resolution 1
(Ordinary)
To receive the Annual Report and Accounts of
the Company for the financial year ended 31 March 2024 together
with the Directors' reports and auditor's report on those
accounts.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 2
(Ordinary)
To receive the Report of the Remuneration
Committee for the financial year ended 31 March
2024.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 3
(Ordinary)
To re-elect Jason Holt as a director of the
Company.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 4
(Ordinary)
To re-elect Dr Michael Hudson as a director of
the Company.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 5
(Ordinary)
To re-elect Professor Sir Christopher Evans OBE
as a director of the Company.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 6
(Ordinary)
To re-elect Professor Trevor Jones CBE as a
director of the Company.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 7
(Ordinary)
To re-appoint PKF Littlejohn LLP as auditor of
the Company.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 8
(Ordinary)
To authorise the Directors to determine the
fees payable to the auditor.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 9
(Ordinary)
To authorise the directors to allot equity
securities pursuant to section 551 of the Companies Act 2006, as
set out in the Notice of Meeting.
|
189,456,532
|
100.00
|
0
|
0
|
0
|
|
Resolution 10
(Special)
To disapply statutory pre-emption rights
generally, as set out in the Notice of Meeting.
|
189,075,584
|
99.84
|
300,000
|
0.16
|
80,948
|
|
Resolution 11
(Special)
To disapply statutory pre-emption rights
pursuant to an acquisition or other capital investment, as set out
in the Notice of Meeting.
|
189,375,584
|
100.00
|
0
|
0
|
80,948
|
As at 30 September 2024, there were 347,357,576
ordinary shares in issue. Shareholders are entitled to one vote per
share. Votes withheld are not votes in law and so have not been
included in the calculation of the proportion of votes for and
against a resolution.
The full text of each resolution is available
in the Notice of Annual General Meeting, published on our
website.
Contacts
|
EDX Medical
Group plc
|
|
|
Dr Mike Hudson (Chief Executive
Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
Oberon
Capital
|
|
|
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
IFC Advisory
(Investor Relations)
|
|
|
Tim Metcalfe
|
+44 (0)20 3934 6630
|
|
Graham Herring
|
|
|
|
|
|
Media House
International
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
Notes for Editors:
About EDX
Medical Group
www.edxmedical.co.uk
EDX Medical Group Plc develops innovative
digital diagnostic products and services, enabling cost effective
and timely delivery of personalised treatment for cancer, heart
disease and infectious diseases. The company is now listed on the
Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic
solutions combining advanced biological and digital technologies,
EDX Medical seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical operates a molecular biology
and diagnostics laboratory in Cambridge, UK, and 100%-owned
subsidiaries "Hutano Diagnostics Ltd", based
in Oxford and "Torax Biosciences Ltd"
in Ireland which together are pioneering the development
of novel point of care tests.
EDX Medical conducts test development and
product validation to ISO 13485 and provides testing and genomic
sequencing services accredited to ISO 15189 by the United
Kingdom Accreditation Service (UKAS).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXFZGFLDGNGDZM
EDX Medical (AQSE:EDX)
Historical Stock Chart
From Oct 2024 to Nov 2024
EDX Medical (AQSE:EDX)
Historical Stock Chart
From Nov 2023 to Nov 2024
